share_log

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin America获选加入全国创伤性脑损伤登记处联盟,以推动创伤性脑损伤的认识和研究工作
GlobeNewswire ·  05/22 20:30

HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition ("Coalition"). This esteemed coalition represents a unified alliance of both private sector entities and non-profit organizations committed to fostering the development of a national TBI registry.

德克萨斯州休斯顿,2024 年 5 月 22 日(GLOBE NEWSWIRE)-- Nexalin 科技股份有限公司 (“公司” 或 “Nexalin”) (纳斯达克股票代码:NXL;NXLIW) 很高兴地宣布,其新部门Nexalin America已被选中加入 全国创伤性脑损伤(TBI)注册联盟 (“联盟”)。这个受人尊敬的联盟代表了私营部门实体和非营利组织的统一联盟,致力于促进国家TBI登记机构的发展。

The Coalition is dedicated to advancing research, raising public awareness, and supporting clinical trials that address traumatic brain injuries, which affect millions each year. By joining the Coalition, Nexalin America underscores its commitment to improving outcomes for TBI patients and enhancing public understanding of this critical health issue.

该联盟致力于推进研究,提高公众意识,并支持针对每年影响数百万人的创伤性脑损伤的临床试验。通过加入该联盟,Nexalin America强调了其致力于改善创伤性脑损伤患者的预后并增进公众对这一关键健康问题的理解。

Other notable members of the Coalition include the NFL Players Association, Spaulding Rehabilitation at Mass General, the United States Brain Injury Alliance, Abbott, and the American Academy of Neurology. This group of diverse partners leverages a wealth of knowledge and resources to drive progress in the treatment and management of brain injuries.

其他值得注意的 会员 该联盟的成员包括美国国家橄榄球联盟球员协会、麻省将军斯波尔丁康复中心、美国脑损伤联盟、雅培和美国神经病学会。这群多元化的合作伙伴利用丰富的知识和资源来推动脑损伤治疗和管理的进展。

As a new member, Nexalin America will play an important role among the private sector partners in the Coalition. The company plans to contribute its background and expertise in neurostimulation technology to support the Coalition's objectives, including the pivotal development of a comprehensive national TBI registry.

作为新成员,Nexalin America将在联盟的私营部门合作伙伴中发挥重要作用。该公司计划贡献其在神经刺激技术方面的背景和专业知识,以支持该联盟的目标,包括全面的国家TBI登记机构的关键发展。

Mark White, CEO of Nexalin, stated, "This partnership with the National TBI Registry Coalition represents a significant step forward in our mission to combat brain injuries through advanced technology and collaborative research. We are excited to work alongside such distinguished organizations and contribute to a cause that has the potential to change lives dramatically."

Nexalin首席执行官马克·怀特表示:“与国家TBI注册联盟的这种合作伙伴关系是我们在通过先进技术和合作研究对抗脑损伤的使命方面向前迈出的重要一步。我们很高兴能与这些杰出组织合作,为一项有可能极大地改变生活的事业做出贡献。”

"We are delighted to have Nexalin as part of the NTRC and excited to see the diversity of companies and organizations joining together to advocate for the creation of a national registry for individuals living with TBI," said Julie Pawelczyk, Executive Director of the Coalition.

该联盟执行董事朱莉·帕维尔奇克说:“我们很高兴Nexalin加入NTRC,也很高兴看到各种各样的公司和组织齐心协力,倡导为TBI患者建立国家登记处。”

The inclusion of Nexalin America in the Coalition not only enhances the group's capabilities but also signals a growing acknowledgment of the crucial role that innovative technologies can play in understanding and treating traumatic brain injuries.

Nexalin America加入联盟不仅增强了该组织的能力,而且也表明人们越来越认识到创新技术在理解和治疗创伤性脑损伤方面可以发挥的关键作用。

The Nexalin America division was established in 2023 with a goal of fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, U.S. Department of Health and Human Services, and other private and public entities.

Nexalin America分部成立于2023年,目标是促进美国国防部、美国退伍军人事务部、美国卫生与公共服务部以及其他私人和公共实体之间的关系。

About Nexalin Technology, Inc.

关于 Nexalin Technology, Inc

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China. Additional information about the Company is available at: .

Nexalin设计和开发创新的神经刺激产品,以独特的方式帮助对抗持续的全球心理健康流行病。Nexalin的所有产品都被认为是非侵入性的,人体无法察觉,其开发目的是为患有心理健康问题的人提供缓解。Nexalin利用生物电子医疗技术来治疗心理健康问题。Nexalin认为,其神经刺激医疗设备可以穿透中脑深处与心理健康障碍相关的结构。Nexalin认为,其下一代设备中更深的穿透波形将增强患者的反应,而不会产生任何不良副作用。Nexalin Gen-2 15 毫安神经刺激设备最近在阿曼和中国获得批准。有关该公司的其他信息可在以下网址获得: 。

FORWARD-LOOKING STATEMENTS

前瞻性陈述

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

本新闻稿包含构成 “前瞻性陈述” 的陈述,这些陈述与未来事件或Nexalin的未来财务业绩有关。任何提及对未来事件或情况的预期、预测或其他描述的陈述,或者不是历史事实陈述的陈述(包括但不限于Nexalin或其管理层 “相信”、“预期”、“预期”、“计划”、“打算” 和类似表述的陈述)都应被视为涉及风险和不确定性的前瞻性陈述,这些陈述可能导致实际事件或Nexalin的实际业绩与前瞻性报告显示的结果存在重大差异声明。前瞻性陈述受许多条件的约束,其中许多条件是公司无法控制的,包括公司截至2023年12月31日的10-K表报告中的风险因素部分以及向美国证券交易委员会提交的其他文件中列出的条件。此类文件的副本可在美国证券交易委员会的网站上找到, www.sec.gov。此类前瞻性陈述自本文发布之日起作出,可能会随着时间的推移而过时。此类前瞻性陈述自本文发布之日起作出,可能会随着时间的推移而过时。除非法律要求,否则公司没有义务在本新闻稿发布之日后更新这些声明以进行修订或变更。

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

联系人:
克雷森多通讯有限责任公司
电话:(212) 671-1020
电子邮件:NXL@crescendo-ir.com

RedChip Companies Inc.
Dave Gentry
407-644-4256
or 407-491-4498
nxl@redchip.com

RedChip Companies
戴夫·金特里
407-644-4256
或 407-491-4498
nxl@redchip.com


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发